Treatment of chronic myeloid leukemia when imatinib fails

Author： Hehlmann Rüdiger   Jung-Munkwitz Susanne   Saußele Susanne  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.2, 2011-02, pp. : 269-283

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment options for chronic myeloid leukemia

By Tanaka Maria Florencia   Kantarjian Hagop   Cortes Jorge   Ohanian Maro   Jabbour Elias  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 6, 2012-04 ,pp. : 815-828

Informa Healthcare

Access to resources Recommend Favorite

Imatinib mesylate in the treatment of chronic myeloid leukaemia

By Druker Brian J  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 6, 2003-06 ,pp. : 963-971

Informa Healthcare

Access to resources Recommend Favorite

Mathematical Modeling of Genesis and Treatment of Chronic Myeloid Leukemia

By  

Cells Tissues Organs, Vol. 188, Iss. 1-2, 2008-02 ,pp. : 236-247

Karger

Access to resources Recommend Favorite

Interferon alpha for Treatment of Chronic Myeloid Leukemia

By  

Current Drug Targets, Vol. 12, Iss. 3, 2011-03 ,pp. : 420-428

Bentham Science Publishers

Access to resources Recommend Favorite

Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?

By Doggrell Sheila A  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 8, 2005-08 ,pp. : 1063-1066

Informa Healthcare

Access to resources Recommend Favorite